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Abstract: Bisphosphonates (BPs) are the most widely used and effective treatment for osteoporosis and Paget's disease. 
Non-nitrogen containing BPs (non-N-BPs), namely etidronate, clodronate, tiludronate, as well as nitrogen-containing BPs 
(N-BPs), namely pamidronate, alendronate, ibandronate, risedronate, zoledronate and minodronate have been launched on 
the market to date. N-BPs act by inhibiting the enzyme farnesyl pyrophosphate synthase (FPPS), and several crystal struc-
tures of complexes between FPPS and N-BPs have been revealed. Understanding the physical basis of the binding be-
tween protein and small molecules is an important goal in both medicinal chemistry and structural biology. In this review, 
we analyze in detail the energetic basis of molecular recognition between FPPS and N-BPs. First, we summarize the inter-
actions between ligands and proteins observed in N-BPs-FPPS complexes in the Protein Data Bank (PDB). Second, we 
present an interaction energy analysis on the basis of full quantum mechanical calculation of FPPS and N-BP complexes 
using the fragment molecular orbital (FMO) method. The FMO result revealed that not only hydrogen bond and electro-
static interaction but also CH- and  interaction with FPPS are important for N-BP’s potency. Third, we describe a 
binding site analysis of FPPS on the basis of the inhomogeneous solvation theory which, by clustering the results from an 
explicit solvent molecular dynamics simulation (MD), is capable of describing the entropic and enthalpic contributions to 
the free energies of individual hydration sites. Finally, we also discuss the structure-activity relationship (SAR) of the se-
ries of minodronate derivatives. 
Keywords: Bisphosphonate, farnesyl pyrophosphate synthase, bone resorption, osteoclast, protein-ligand binding, drug design. 
1. INTRODUCTION 
Minodronate (minodronic acid, YM-529, Ono-5920, YH-
529), a third-generation Bisphosphonate (BP) originally de-
veloped at Astellas Pharma (formerly Yamanouchi), was 
approved and launched in 2009 in Japan for the oral treat-
ment of osteoporosis. Minodronic acid, which was synthe-
sized by a team of medicinal chemists lead by one of the 
authors (M. Takeuchi), has been shown to have 100- to 
1000-fold higher bone resorption activity than pamidronate 
[1]. 
BPs are the most widely used and effective treatments for 
osteoporosis and Paget's disease [2, 3]. In addition to mino-
dronate, etidronate (Proctor & Gamble, 1977), clodronate 
(Bayer, 1986), pamidronate (Gador/Novartis, 1987), alen-
dronate (Abiogen/Merck, 1993), tiludronate (Sanofi-Aventis, 
1995), ibandronate (Roche, 1996), risedronate (Sanofi-
Aventis, 1998), and zoledronate (Novartis, 2000) have been 
launched on the market. Their chemical structures are shown 
in Fig. (1). Chemically, BPs are characterized by two phos-
phonate groups linked to a central carbon atom, forming a P-
C-P structure [2,3]. They can be divided according to   
differences in the side chain into two groups, non-nitrogen 
containing BPs (non-N-BPs) and nitrogen-containing BPs 
(N-BPs), which are further classified into two additional 
groups, alkyl-amino BPs and heterocyclic N-BPs [4,5] (Fig. 
1). BPs inhibit osteoclast formation in vitro, disrupt the   
osteoclast cytoskeleton and ruffled border, and can cause 
osteoclast apoptosis [6]. The anti-resorptive potency of BPs 
has long been known to be influenced by the chemical   
structure of the side chain attached to the central   
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carbon of the P-C-P backbone. It is thought that the mecha-
nism of intracellular action differs between non-N-BPs and 
N-BPs. Non-N-BPs are metabolized in the osteoclast cytosol 
to non-hydrolyzable cytotoxic adenosine triphosphate (ATP) 
analogues that induce osteoclast apoptosis, while the more 
potent N-BPs inhibit farnesyl pyrophosphate synthase 
(FPPS), a key enzyme in the mevalonate pathway (Fig. 1) [7-
12]. FPPS (EC 2. 5. 1. 10) is a homodimeric enzyme of 41-
kD subunits which catalyzes the sequential condensation of 
isopentenyl pyrophosphate (IPP), first with dimethylally 
pyrophosphate (DMAPP) and then with the resultant geranyl 
pyrophosphate (GPP) to produce the C15 farnesyl pyrophos-
phate (FPP). Inhibition of FPPS in osteoclasts prevents the 
biosynthesis of isoprenoid lipids that are required for the 
prenylation of small GTPase signaling proteins necessary for 
osteoclast function. Several crystal structures of human 
FPPS complexed with N-BPs have been reported (Table 1). 
Similarly, N-BPs have been shown to inhibit farnesyl pyro-
phosphate/geranyl pyrophosphate synthase activity 
(GGPPS). Some N-BPs can inhibit GGPPS as well as FPPS 
[13]. 
The potency of a wide range of BPs to FPPS has been in-
vestigated [14]. To date, many researchers have analyzed the 
forces driving the formation of complexes between FPPS 
and N-BPs using experimental approaches. Yin et al. used 
isothermal titration calorimetry (ITC) to reveal the thermo-
dynamic properties of binding between T. burucei FPPS and 
N-BPs, and showed that the binding of risedronate is en-
thalpy driven, whereas that of zoledronate is entropy driven 
[15]. Kavanagh et al. also applied the ITC method to reveal 
the thermodynamic properties of binding between human 
FPPS and N-BPs. In contrast to Yin et al. [15], they indi-
cated that the binding of both risedronate and zoledronate are 
entropy driven [16]. The force driving the binding of FPPS 
and N-BPs thus remains unclear. In general, enthalpy-driven 
binding has several advantages over entropy-driven binding 
with regard to solubility and selectivity, and a deep under-Computational Insights into Binding of Bisphosphates  Current Medicinal Chemistry,  2011 Vol. 18, No. 2      221 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Schematic diagram of the mevalonate pathway and the chemical structures of bisphosphonate drugs. The formation of intracellular 
metabolites of non-N-BPs in osteoclasts induce osteoclast apoptosis, while N-BPs, including alkyl-amino BPs and heterocyclic N-BPs inhibit 
FPPS, thereby preventing the synthesis of FPP and GPP, which are required for protein prenylation. N-BPs also can induce formation of an 
ATP analog (ApppI) as a consequence of inhibition of the mevalonate pathway. The IC50 data was obtained from reference [16].  
 
Table 1.  Summary of FPPS Structures 
 
pdb code  resolution/Å  ligand  mutation  calculation  reference 
3B7L  1.95   minodronate, Mg    Yes  [20] 
2VF6  2.10   minodronate, Mg      [20] 
2F8C  2.20   zoledronate , Mg    Yes  [21] 
2F8Z  2.60   zoledronate, Mg, IPE      [21] 
2F9K  2.06   zoledronate, Zn, PO4      [21] 
1ZW5  2.30   zoledronate, Mg, IPR      [16] 
1YV5  2.00   risedronate, Mg, PO4    Yes  [16] 
1YQ7  2.20   risedronate, Mg, PO4      [20] 
2QIS  1.80   risedronate, Mg  T210S    [20] 
2F94  1.94   ibandronate, Zn, PO4    Yes  [21] 
2F92  2.15   alendronate, Zn, PO4    Yes  [21] 
2F89  2.60   pamidronate, Mn, PO4    Yes  [21] 
IPE, IPR and PO4 mean 3-methylbut-3-enyl trihydrogen diphosphate, isopentyl pyrophosphate, and phosphate ion, respectively. In this report, 3B7L, 2F8C, 1YV5, 2F94, 2F92, and 
2F89 were used for calculation. 222    Current Medicinal Chemistry,  2011 Vol. 18, No. 2  Ohno et al. 
standing of the driving force would therefore facilitate the 
design of better compounds. 
This review proceeds as follows. In the first section, we 
summarize the interaction between currently on-market 
bisphosphates and FPPS in Protein Data Bank (PDB). In the 
second section, we conduct an interaction energy analysis 
using the ab initio fragment molecular (FMO) method. In the 
third section, we analyze the hydration of binding site in 
FPPS on the basis of inhomogeneous solvation theory which, 
by clustering the results from an explicit solvent molecular 
dynamics (MD), is capable of describing the entropic and 
enthalpic contributions to the free energies of individual hy-
dration sites. Finally, we discuss the structure-activity rela-
tionship (SAR) of a series of minodronate derivatives. 
2. STRUCTURAL BASIS FOR THE RECOGNITION 
OF N-BPs BY FPPS 
FPPS, one of the key regulatory enzymes in the me-
valonate pathway and also the major target enzyme of N-
BPs, is a single family which was first characterized by two 
aspartic-rich motifs with the consensus DDXXD sequence 
(X indicates any residues), which is highly conserved 
amongst isoprenyl synthases [17,18]. For catalytic activity, 
the presence of magnesium ions is required and Cornforth et 
al. have revealed that the reaction of FPPS occurs via  a 
three-metal ion catalytic mechanism [17] (Fig. (2a)). The 
DDXXD motifs are important for ensuring the proper ar-
rangement of three magnesium ions in the active site of 
FPPS [18]. 
Understanding the recognition of protein interaction sites 
is a critical step toward understanding the function of the 
protein, identification of functionally relevant amino acid 
residues, comparison and profiling of the ligands, and the 
structure-based drug design process. Recent technological 
innovations such as high-throughput crystallization and high 
performance synchrotron beam lines have enhanced the 
value of the technique further [19]. 
Crystallographic studies of human FPPSs of apo- and 
complex-forms with N-BPs (Table 1) [16,20,21] revealed 
that (1) human FPPS is a homodimeric enzyme of 41-kDa 
subunits, (2) FPPSs have two substrate pockets, a 
DMAPP/GPP-binding site and an IPP-binding site (Fig. 
(2b)), (3) N-BPs bind to the DMAPP/GPP-binding pocket 
(Fig. (2b)), thereby acting as competitive inhibitors of this 
binding site as carbocation transition state analogs, (4) N-
BPs’ binding causes a conformational change of FPPS which 
induces the closing of the active-site cavity by a rigid body 
motion of the last 130 C-terminal amino acids residues of the 
enzyme (Fig. (2b)), and (5) the binding of IPP causes fully 
closed conformation and stabilization of the FPPS-N-BP 
complexes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). a) A schematic showing three-metal ion catalytic mechanism of the FPPS enzyme. b) three-dimensional view of DMAPP/GPP-
binding site and IPP-binding site of our modelled complex of minodronate (blue), IPP (blue) and closed form of FPPS (white ribbon). This 
model was constructed using the crystal structures of minodronate-FPPS complex (PDB id: 3B7L) and zoledronate-IPP-FPPS complex (PDB 
id: 2F8Z) as templates. The orange ribbon shows the open form of unligated FPPS (PDB id: 2F7M). The pink arrow indicates the conforma-
tion change induced by the ligand binding. Computational Insights into Binding of Bisphosphates  Current Medicinal Chemistry,  2011 Vol. 18, No. 2      223 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). The interaction in N-BPs-FPPS complexes. a) LigPlot interactions in minodronate-FPPS complex (PDB id: 3B7L). b) LigPlot inter-
actions in zoledronate-FPPS complex (PDB id: 2F8C). c) LigPlot interactions in risedronate-FPPS complex (PDB id: 1YV5). d) LigPlot in-
teractions in ibandronate-FPPS complex (PDB id: 1F94). e) LigPlot interactions in alendronate-FPPS complex (PDB id: 1F92). f) LigPlot 
interactions in pamidronate-FPPS complex (PDB id: 1F89). Green circles represent metal ions, such as Mg
2+, Zn
2+, or Mn
2+ ion. Dashed red 
lines shows the hydrogen bonding or polar interactions between N-BPs and FPPS and dashed green lines shows the interactions of the metal 
ions with N-BPs or FPPS. Dashed orange line show  interaction. 
Fig. (3) shows schematic representations summarizing 
the binding of the N-BPs minodronate, zoledronate, risedro-
nate, ibandronate, alendronate and pamidronate to FPPS. 
Images were created using the program LigPlot
+ v.1.0, which 
generates schematic 2-D representations of protein-ligand 
complexes from the PDB file input [22]. The IDs of the PDB 
files used in the LigPlot calculation are 3B7L (minodronate), 
2F8C (zoledronate), 1YV5 (risedronate), 2F94 (ibandronate), 
2F92 (alendronate) and 2F89 (pamidronate), which are 
summarised in Table 1. As shown in Fig. (3), all N-BPs have 
common P-C-P structures and their interactions are the same, 
wherein the bisphosphonate moiety of the N-BP binds to a 
trinuclear Mg
2+ cluster (Fig. (2a)), and all three magnesium 
ions are octahedral coordination and linked with the car-224    Current Medicinal Chemistry,  2011 Vol. 18, No. 2  Ohno et al. 
boxylate groups of the side chains of Asp103 and Asp107 in 
the first DDXXD motif and Asp243 in the second DDXXD 
motif, and water molecules. Two of three magnesium ions 
form rather symmetrical six-membered rings, with the 
bisphosphonate acting as a bidentate chelate, while one mag-
nesium ion forms an additional single chelate. There are also 
direct salt bridge interactions of conserved residues Arg112, 
Lys200 and Lys257 of FPPS with the bisphosphonate moiety 
in all N-BPs. Because Lys257 is the residues in the HI loop 
(Fig. (2b)), the interaction between Lys257 and BPs is 
thought to contribute to stabilizing the closed conformation 
of FPPS. It is reported that the OH group on the carbon atom 
in the P-C-P structure in N-BPs, together with the two phos-
phate groups in this structure, is responsible for the N-BPs’ 
high affinity to bone mineral [23]. However, the OH group 
also contributes to FPPS binding via the polar interaction 
with Asp243 (Fig. 3). 
On the basis of the differences in the side chain, N-BPs 
can be classified into two groups [4, 5], the heterocyclic N-
BPs, which include minodronate, zoledronate, and risedro-
nate; and the alkyl-amino BPs, which include ibandronate, 
alendronate, and pamidronate (Fig. 1). Using solid-state 
NMR, Mao et al. showed that N-BPs bind to FPPS via their 
protonated side chain [24]. Their results are supported by not 
only the crystallographic studies [1,16,20,21] but also our 
analysis using FMO calculation, which is described in the 
next section (direct interaction of Thr201). In all three het-
erocyclic N-BPs, minodronate, zoledronate and risedronate, 
the protonated heterocyclic nitrogen undergoes hydrogen 
bonding to both the hydroxyl group of Thr201 and the back-
bone carbonyl oxygen of Lys200 (Fig. (3a), (3b) and (3c)). 
The amino groups of alendronate and pamidronate, which 
belong to the alkyl-amino BPs, also interact with the hy-
droxyl groups of Thr201 and Tyr204, respectively (Fig. (3d) 
and (3e)). However, such bifurcated hydrogen bonding is 
only formed in heterocyclic N-BPs. These strong interactions 
of the protonated heterocyclic rings are thought to be one of 
the reasons why heterocyclic N-BPs have higher binding 
affinities for FPPS and greater inhibitory potency against the 
biochemical effect than alkyl-amino BPs. Fig. (3) also shows 
the hydrophobic contacts between FPPS and N-BPs. As 
shown in this figure, minodronate, which has a bulky bi-
cyclic ring, and ibandronate, which has a long hydrophobic 
side chain, have a large number of hydrophobic contacts 
(Fig. (3a) and (3d)) compared with the other N-BPs. Moreo-
ver, these two N-BPs show tighter binding affinities than 
others in their respective classification (alkyl-amino BPs: 
ibandronate > alendronate, pamidronate; heterocyclic N-BPs: 
minodronate > zoledronate, risedronate). Minodronate is the 
only N-BP which has both bifurcated hydrogen bonding and 
a large number of hydrophobic contacts. These interactions 
are thought to make minodronate the most potent drug 
among BPs. 
3. INTERACTION ANALYSIS BY FMO CALCULA-
TION OF FPPS WITH N-BPs 
We tried to understand the physical basis of the interac-
tion between FPPS/N-BPs using in silico technology. There 
are two major in silico approaches: molecular mechanics 
(MM) and quantum mechanics (QM). The MM approach is 
very fast, but is limited by its inability to describe noncan-
onical interaction such as CH-, CH-O hydrogen bond, and 
 correctly. In contrast, the QM approach overcomes the 
above issue, but its computational time is too long for practi-
cal use. The QM/MM method is one of the most promising 
methods of avoiding this problem [25]. However, QM/MM 
has its own problem, namely the boundary between the QM 
and MM parts, which causes an inevitable artificial error in 
energy.  
The fragment molecular orbital (FMO) method, origi-
nally developed by Kitaura, enables the analysis of a whole 
protein-ligand complex by quantum mechanical calculation 
without any of the issues described above.[26] The FMO 
method has been applied to many biomolecular systems to 
describe protein-ligand interaction in detail.[27,28] Here, to 
analyze the contribution from each amino acid residue to the 
interaction, we employed the FMO method as implemented 
in GAMESS to calculate the interaction energy of bisphos-
phonate compounds for FPPS. In the FMO method, a protein 
is divided into fragments based on the amino acid unit (Fig. 
(S1a)). It should be noted that the i-th fragment in FMO does 
not completely correspond to the i-th amino acid residue. 
The i-th fragment includes the carbonyl group of the (i-1)-th 
amino acid backbone but does not include that of the i-th. 
For example, the Thr201 fragment contains the Lys200 
backbone carbonyl but does not contain carbonyl of Thr201. 
The contribution of the P-C-P part to total energy is negligi-
ble, because it is common in all N-BPs. Therefore, in the 
following paragraphs in this section, we focus on the interac-
tion of N-BPs’ side-chain with these amino acids. 
For accurate comparison of interaction energy, we used 
coordinates created by superposing the PDB structures over 
3B7L and minimizing the proximate residues within 4.5 A 
from the ligand, which was replaced with minodronate. All 
water molecules were retained except for the molecule (resi-
due number 1060 in 3B7L) in the ibandronate model, due to 
the molecule’s overlap with the heavy atoms of ibandronate. 
Mg910 in 3B7L seems to be a miss-assignment in X-ray 
modeling, because (1) a water molecule occupies this site in 
the other FPPS-ligand complexes, (2) no ligand for the Mg 
exists, and (3) no statement on metal coordination of Mg910 
is written in the PDB data file. Therefore, we replaced 
Mg910 with a water molecule for FMO calculations. The 
coordinates of missing atoms and side chains were assigned 
by Maestro. Protonate3D in MOE was then used to assign 
the coordinate of hydrogen atoms of residues with a titratable 
group and polar hydrogen atoms. According to a previous 
study that demonstrated that N-BPs have a protonated side 
chain [24], the protonated form was used in FMO calcula-
tion. N-BPs was divided into two fragments (Fig. (S1b)), and 
FPPS was fragmented into one fragment per residue in the 
FMO standard fashion (Fig. (S1a)). All three Mg ions in the 
binding site were united into the P-C-P fragment of N-BP. 
Single point FMO2-MP2/6-31G calculations of all FPPS-N-
BP complexes were carried out. Pair interaction energy de-
composition analysis (PIEDA)[29] was used for analysis of 
detailed comparisons of interaction energy due to the differ-
ence in N-BP. FMO calculations were done using GAMESS 
version January 12, 2009, R3 for 64 bit Linux with Intel 
compilers [30]. Computational Insights into Binding of Bisphosphates  Current Medicinal Chemistry,  2011 Vol. 18, No. 2      225 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). PIE (in kcal/mol) of N-BP with FPPS. Yellow and red bars represent contribution of sidechain and P-C-P fragments, respectively. 
For clarity, PIE values of N- and C-terminal residues are not shown, as no significant difference was observed. 
First, we overviewed how the difference in N-BPs af-
fected the interaction energy between FPPS and N-BPs. Fig. 
(4) shows fragment pair interaction energy difference (PIE) 
decomposed into each residue, taking minodronate as a ref-
erence. Having found several common regions which were 
affected by the difference in the side chain of N-BPs, we 
investigated in detail precisely which residue contributes to 
the interaction energy by calculating variance of PIE of each 
residue. Variance is a measure of how far vlaues are distrib-
uted from the mean. Therefore, the variance of PIE values 
with different N-BPs indicates the residue’s sensitivity to the 
difference in N-BPs. Fig. (5a) shows the variance of PIE of 
each residue. There were 14 residues mainly affected by the 
difference: Arg60, Phe99, Leu100, Asp103, Asp107, 
Arg112, Glu168, Gln171, Lys200, Thr201, Gln240, Asp243, 
Asp244, and Lys257. Interestingly, some of the residues 
with direct contacts as drawn in Fig. (3) were not among 
these 14 residues, indicating that not all of the residues near 
N-BP are important for binding or that current N-BPs cannot 
make use of all the residues. Surprisingly, the PIE of 
Asp103, Asp107, Arg112, Asp243, and Lys257 were corre-
lated with potency (Fig. (5b)) although these residues have 
direct contact with only the common P-C-P part, indicating 
that the side-chain replacements of N-BPs have both direct 
and indirect effects on the interaction energy. We further 
investigated which residues vary and correlate with the po-
tency of N-BPs by calculating covariance values between 
PIE and pIC50 (Fig. (5b)). Covariance is a measure of how 
much two variables vary together. Covariance differs from 
correlation in that covariance takes into consideration the 
magnitudes of two variables, whereas correlation normalizes 
the magnitudes. Given that, in the present study, we were 
interested only in those residues with PIE values varing 
largely in correlation with the potency, we adopted covari-
ance over correlation as the preferred parameter to determine 
which residues have an impact on potency. The covariance 
between PIE and pIC50 of N-BPs clearly indicates that six 
residues tend to increase PIE as pIC50 becomes larger, 
namely Arg60, Leu100 (plus carbonyl oxygen atom of 
Phe99), Glu168, Lys200, Thr201, and Lys257. In addition, 
the covariance reveals that obtaining a smaller PIE with the 
other eight residues described above increases the potency of 
N-BPs. In the following paragraphs, we show the decompo-
sition of these interactions and discuss them in detail. 226    Current Medicinal Chemistry,  2011 Vol. 18, No. 2  Ohno et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Residues sensitive to the difference in N-BP side chain. (a) Variance of PIE of each residue (unit is square of kcal/mol). (b) Covari-
ance between PIE of each residue and pIC50 of N-BPs (unit is –log10(mol)*kcal/mol). (c) Molecular graphics of FPPS and minodronate. The 
residues with large variance in PIE are shown. The atoms are colored according to the element, and the carbon atoms of minodronate are col-
ored yellow. The residues with direct contacts with the N-BP sidechain are labeled in yellow and others in white. Hydrogen bonds and  
interactions are represented by sky-blue and orange dashed lines. (d) Summary of the direct effect achieved with sidechain replacement of N-
BPs. Hydrogen bonds and  interaction are represented by sky-blue and orange lines. The residues involved in the hydrogen bonding are 
labeled in yellow. Non-polar hydrogen atoms, hydrogen atoms involved in hydrogen bonding, and heavy atoms are also shown. The green 
surface represents the molecular surface of the binding pocket. For clarity, the molecular surface of the pocket in front of the N-BPs has been 
deleted. 
Direct Effect 
In the 14 residues with large variance in PIE, Phe99, 
Leu100, Gln171, Lys200, and Thr201 have direct contact 
with the N-BP side chain. Moreover, four of the five have a 
correlation between the augmentation of their PIE and po-
tency (Fig. (5b)). Moreover, it should be noted that, in FMO, 
the PIE of the hydrogen bond of the carbonyl oxygen atom 
of Lys200 is included in the PIE of Thr201. Because the only 
contact point of Lys200 with the N-BP sidechain is the 
backbone carbonyl oxygen atom, we focus here on describ-
ing the PIE of Phe99, Leu100, and Thr201. PIEDA decom-
poses PIE into an electrostatic (ES), exchange-repulsion 
(EX), charge transfer plus higher-order mixed term 
(CT+mix), and dispersion (DI). PIEDA can therefore de-
scribe any PIE in detail. Table 2 shows the result of PIEDA 
for Phe99, Leu100, and Thr201.  Computational Insights into Binding of Bisphosphates  Current Medicinal Chemistry,  2011 Vol. 18, No. 2      227 
Phe99 can be utilized well by minodronate and slightly 
by risedronate (Table 2). Minodronate interacts with Phe99 
via  interaction and via CH-O hydrogen bonding. The 
large nitrogen-containing electron-deficient imidazopyridine 
ring of minodronate allows to interact with the side chain of 
Phe99  via   interaction effectively. In addition to the 
fragment Phe99, minodronate shows remarkably large attrac-
tive energy with the fragment Leu100. It should be noted that 
minodronate transfers a much larger amount of charge (Ta-
ble 2). Looking into the complex structure (Fig. (5c)), we 
find that an aromatic hydrogen atom of the imidazopyrizine 
ring forms a CH-O bond with the backbone carbonyl group 
of Phe99, whose energy is integrated into the PIE of the 
fragment Leu100 in FMO. The finding of large ES and 
CT+mix terms also supports the notion that this interaction is 
achieved via hydrogen bonding. This results in the large at-
tractive energy of minodronate for the fragment Leu100, 
because the sidechain of Leu100 interacts equally with the 
common methylene group of all the N-BPs. Therefore, 
Phe99 plays an important role in stabilizing N-BP binding, 
particularly for N-BPs with a large sidechain, like minodro-
nate. 
Hydrogen bonds with oxygen atoms of a backbone of 
Lys200 and sidechain of Thr201 is critical for the potency of 
N-BPs. In FMO, the interaction energy of the two hydrogen 
bonds is integrated into the PIE of the fragment Thr201. Ta-
ble 2 indicates that the PIE of the fragment Thr201 depends 
almost completely on the ES term. This is reasonable be-
cause all N-BPs have a cationic nitrogen atom proximate to 
the oxygen atoms of Lys200 and Thr201. Interestingly, het-
erocyclic N-BPs have approximate 2-fold greater interaction 
than the others. This is due to the bifurcated hydrogen bonds 
with Lys200 and Thr201, which are characteristic of hetero-
cyclic N-BPs, as described in the previous section. 
To summarize the direct effects (as also shown in Fig. 
(5d)), the following interactions are likely important for the 
potency or N-BP: (1) hydrogen bonding with Thr201 and/or 
Lys200, with bifurcated hydrogen bonds likely to have 
greater potency than single bonds, (2) CH-O hydrogen bond-
ing with the backbone carbonyl oxygen atom of Phe99, and 
(3)  interaction with the sidechain of Phe99. Among N-
BPs, only minodronate satisfies all three conditions, which is 
likely one reason for its higher potency than the others. 
Indirect Effect 
Fig. (5b) indicates that the potency of N-BPs correlates 
positively or negatively with the PIE of Arg60, Asp103, 
Asp107, Glu168, Lys200, Asp243, and Lys257. This is sur-
prising because all have direct contact with the P-C-P portion 
of the N-BP and Mg ions, which are common in all N-BPs. 
In the FMO used in this study, their coordinates are com-
pletely identical. The seven residues have one unit of posi-
tive or negative charge on their sidechain. We therefore 
Table 2.  Decomposed Pair Interaction Energy (in kcal/mol) and Charge Transfer (in a.u.) between the Sidechain of N-BPs and 
FPPS 
 
Fragment
a) Inhibitor  Total  ES
b) EX
b) CT+mix
b) DI
b)  Q
c) 
minodronate -2.8 -2.5 5.0  -1.6 -3.7  0.0047 
zoledronate 0.10  0.31  0.0010  -0.036  -0.17  0.00 
risedronate -0.39  0.086  0.017  -0.090  -0.41  0.00 
ibandronate 4.4 -7.1  23 -3.0 -8.7  0.013 
alendronate 0.50  0.61  -0.0010  -0.010  -0.090  0.00 
Phe99 
pamidronate 0.77 0.85  -0.0010  -0.0090  -0.069  0.00 
minodronate -11 -9.8 4.7 -1.7 -4.1  0.019 
zoledronate -5.3 -4.4  0.76  -0.45  -1.2  0.0021 
risedronate  -6.2 -5.1 1.2 -0.57 -1.7  0.0023 
ibandronate -6.0 -5.9 4.2 -1.2 -3.1  0.0069 
alendronate -4.0 -3.3 1.2 -0.52 -1.3  0.0020 
Leu100 
pamidronate -4.9 -4.3 1.1 -0.56 -1.2  0.0032 
minodronate -45 -45 10  -3.9 -5.9  0.056 
zoledronate -45 -43 6.4 -3.2 -4.7  0.042 
risedronate -49 -58 21 -5.2  -6.3  0.067 
ibandronate -22 -28 13 -2.9 -4.8  0.035 
alendronate -35 -43 16 -5.5 -3.3  0.054 
Thr201 
pamidronate -24 -22  0.078  -0.82  -0.81  0.0065 
aThe i-th fragment in FMO does not completely correspond to the i-th amino acid residue. The i-th fragment includes the carbonyl group of the (i-1)-th amino acid backbone but not 
that of the i-th. 
bES, EX, CT+mix, DI represent electrostatic, exchange-repulsion, charge transfer plus higher-order mixed terms, and dispersion contribution, respectively.  
cQ is amount of charge transferred from the residue to side chain of N-BP. Charges are derived from two-body Mulliken atomic charges calculated using the FMO2-MP2/6-31G 
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speculated that the difference in PIE might be caused by 
changes in the ES term of PIE due to (1) change of atomic 
charge on the P-C-P by sidechain replacement and (2) posi-
tive charge delocalization on the sidechain of N-BP. To in-
vestigate these possibilities, we performed PIEDA of the PIE 
of these residues at first (data not shown). The results indi-
cated that PIE was dependent on the ES term. We then inves- 
tigated which part of N-BPs affects the difference (Table 
S1). Results showed that PIE of Arg60, Glu168, Lys100, 
Asp243, and Lys257 depends on the sidechain, while those 
of Asp103 and Asp107 depend on both the P-C-P and 
sidechain. Furthermore, we looked into the amount of charge 
of N-BPs transferred from the surrounding residues (Table 
S2). The results do not show a clear relationship with PIE. 
It should be noted, however, that the basis set used in this 
study (6-31G) may underestimate the charge transfer associ- 
ated with anions due to the lack of a diffuse function. Results 
may be improved by using a more extensive basis set, such 
as 6-31+G or 6-31+G*. Taking all results into account, the 
influence of the change in atomic charge due to charge trans- 
fer cannot explain the PIE. We then investigated the delo- 
calization of the positive charge on the sidechain of N-BP 
(Fig. S2). As expected, minodronate delocalizes its positive 
charge on the sidechain so that the positive charge reaches 
the tip of the heterocyclic ring, which decrease the electro- 
static expulsion and attraction by the positively charged and 
negatively charged residues in the proximate P-C-P part of 
the N-BP, respectively. This delocalization leads to an in- 
crease in the electrostatic attraction energy between N-BP 
and Glu168, because Glu168 is located on the inverse side of 
the P-C-P binding site. 
In summary, sidechain replacement of N-BP affects the 
electrostatic interaction with surrounding residues mainly 
due to the position of the positive charge on the sidechain. 
FMO calculation suggests that the delocalization tends to (1) 
stabilize interaction between N-BP and positively charged 
residues and (2) decrease electrostatic attractive energy by 
acidic residues, and (3) stabilize the interaction between N-
BP and Glu168. Because the residues involved in the former 
two are located in the P-C-P binding site, the effect of (1) 
and (2) is trade-off relationship to ensure little impact on the 
increase in binding energy. FMO calculation suggests that 
Glul68 might be another contributor to the potency of N-
BPs. However, Glul68 is exposed to solvent, and the electro-
statical interaction might therefore be shielded. 
4. HYDRATION IN THE POCKET OF FPPS 
MD simulation is widely used to investigate the confor-
mational change of proteins. For example, Sigman et al. 
conducted MD simulation for T. cruzi FPPS to reveal the 
conformational change induced by Mg
2+ binding [31]. Re-
cently, MD simulation of water molecules in active sites has 
gained considerable attention in the drug discovery field. 
When a ligand binds to a protein, the water in the active site 
is driven from the active site into the bulk fluid. This expul-
sion of the active-site solvent affects the binding free energy 
of the complex both enthalpically and entropically. When 
energetically or entropically unfavourable water molecules 
are expelled, the contribution of this expulsion to the binding 
free energy is favourable. Recently, Friesner’s group devel-
oped a novel, computationally efficient method to analysis 
environments for solvating water in the active site pockets 
(WaterMap method) [32]. The WaterMap method can pro-
vide deep insights into molecular recognition at low compu-
tational cost. To date, several applications of this method 
have been developed [33,34]. These have shown that the 
active sites of COX-2 and Factor Xa provide very diverse 
environments for solvating water in the active site. Further-
more, the calculated relative difference in binding free en-
ergy is well consistent with the experimental one. 
To built an input file for the WaterMap method, each 
three-dimensional coordinate of the FPPS/BP complex was 
obtained from Protein Data Bank (Table 1). The addition of 
hydrogen atoms was conducted using MOE 2006.08 [35] and 
the energy minimization calculation was carried out using 
Maestro 8.5 ed. (Schrodinger) [36]. The WaterMap method 
has been described in detail elsewhere [33]. MD simulations 
were conducted using the Desmond molecular dynamics 
engine [37]. The OPLS2005 force field was used [38,39]. 
The energy minimized structure was used as a initial coordi-
nate. Atoms of FPPS were truncated beyond 15 Å of the 
ligand. The ligand was not included in the system. The re-
sulting protein construct was solvated in a TIP4P water box 
extending at least 5 Å beyond the FPPS in all directions. 2ns 
MD simulation with positional restraints on the protein non-
hydrogen atoms was performed following the default relaxa-
tion protocol, including successive stages of minimization 
and heating. Water molecules in the active site were clus-
tered to form hydration sites. The enthalpy term was ob-
tained from the average non-bonded energy of each hydra-
tion site. The excess entropy term was obtained by numeri-
cally integrating a local expansion of spatial and orienta-
tional correlation functions. [32,40,41] In the entropy calcu-
lation, only contributions from the first order term of the 
expansion were taken into account. Ligand binding energies 
were then estimated as the sum of hydration site (hs) free 
energies that are displaced by ligand atoms (lig) upon bind-
ing. The function for the G of binding is  
 
Gbind = Ghs
lig,hs  1

rlig 

rhs
RCO







	
	
(R CO 

rlig 

rhs )      (eq. 1) 
where, Rco is the cutoff distance for a ligand atom to begin 
displacing a hydration site, Ghs is the computed free energy 
of transferring the water molecule in a given hydration site 
from the active site to the bulk fluid, and  is the Heaviside 
step function. The value of Rco was selected as 2.24. [32]  
The results for each hydration site are summarized in Ta-
ble  S3. There are large differences in the thermodynamic 
properties of hydration sites, which indicates that the active 
site of FPPS provides very diverse environments for solvat-
ing water. As stated by Friesner’s group and researchers at 
Schrodinger Inc., those of COX-2, Factor Xa and the PDZ 
domain also provide markedly varied environments for ac-
tive site water molecules [32-34]. As shown in Table S3, the 
enthalpy contributions of hydration site 12 and 20 have posi-
tive values, which indicates that water molecules in these 
hydration sites are enthalpically unfavourable. Thus, the ex-
pulsion of the water molecule in these hydration sites makes 
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ergy. In contrast, the enthalpy contributions of hydration site 
1, 2, 5, and 6 are under -7 kcal/mol, which indicates that wa-
ter molecules in these hydration sites are enthalpically fa-
vourable. Thus, the expulsions of water molecules in these 
hydration sites makes an enthalpically unfavourable contri-
bution to binding free energy. Although the enthalpic contri-
butions of almost all hydration sites have negative values, 
those of FPPS are somewhat larger than those of Factor Xa 
[32]. On the other hand, the entropic contribution of each 
hydration site has a positive value. This means that the ex-
pulsion of water molecules has an entropically favourable 
effect on binding free energy. 
Fig. (6) shows the three-dimensional hydration map. In 
Fig. (6a), hydration sites whose G values were less than -
3.0 kcal/mol (1, 5, 6, 7, 13, 14, and 18) are shown in green 
cubes. These hydration sites overlapped the P-C-P backbone 
structure. In Fig. (6b), the hydration sites whose H have a 
positive value (12 and 20) are shown in red cubes. These 
hydration sites overlapped the imidazopyridine ring of mino-
dronate. Details of the properties of individual sites are 
shown in supplemental material Table S4. In the case of hy-
dration sites 12 and 20, there were large differences in ther-
modynamics properties among inhibitors. For example, in 
the case of hydration site 12, the G values of minodronate 
and ibandronate were somewhat smaller than those of zole-
dronate, alendronate, and pamidronate, by 4 kcal/mol. In the 
case of hydration site 20, those of minodronate and ibandro-
nate were also somewhat smaller than those of alendronate 
and pamidronate, by 4 kcal/mol. These differences arise 
from the fact that minodronate and ibandronate can expel the 
unstable water molecules in hydration sites 12 and 20 (Fig. 
(6b)) whereas alendronate and pamidronate cannot. In con-
trast, in the case of hydration site 6, G is quite large, and 
there is no difference among BPs. These results indicate that 
although the expulsion of water molecules in hydration site 6 
has a large effect on the binding free energy, all BPs can 
expel the water molecule in hydration site 6. 
The purpose of this part of the study was to investigate 
the energetic basis of molecular recognition between FPPS 
and BPs using MD calculations of solvating water mole-
cules. From the results of MD calculation, the environment 
for solvating water molecules was shown to be very diverse. 
Furthermore, we showed that minodronate and ibandronate 
can expel water molecules in these hydration sites (12 and 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). The hydration sites in the active site of FPPS. (a) Minodronate and hydration sites whose G values were below -3.0 kcal/mol; (b) 
minodronate and hydration sites whose H had a positive value. 230    Current Medicinal Chemistry,  2011 Vol. 18, No. 2  Ohno et al. 
20), which usually cause a significant affinity increase. It is 
noteworthy that minodronate is the only bisphosphonate 
which has the following two merits: (1) exclusion of unstable 
water molecules in the active site pocket and (2) strong in-
teraction with Lys200 and Thr201, as mentioned in the pre-
vious section. In fact, minodronate has the strongest activity 
in vitro and in vivo among launched BPs.  
5. RE-CONSIDERATION OF STRUCTURE-ACTI-
VITY RELATIONSHIP OF HETEROCYCLIC N-BPs 
In early research into BPs conducted since the late 1960s 
by many pharmaceutical companies, the target of BPs was 
unknown and BPs were thought to act by modulating bone 
mineral dissolution [42]. The SAR of activity in inhibiting 
bone resorption was therefore the only information for me-
dicinal chemists, and the structure-based drug design 
(SBDD) approach using the three dimensional structure of 
the target enzyme and SAR analysis using direct in vitro 
activity of enzyme inhibition could not be applied. Table 3 
shows our previously published data on the structures of our 
heterocyclic series of minodronate derivatives [1,43], their 
clogP values of the side chain, and their experimental antire-
sorptive activities. Our early research found that the bulki-
ness and lipophilicity of the side chain of N-BPs were impor-
tant determinants of their antiresoptive activity [43]. How-
ever, compound 1, having an equivalent clogP value, an in-
dex of lipophilicity as minodronate, and the compounds 2 
and 3, having clogP values greater than that of minodronate, 
showed remarkably decreased potency, whereas compound 
4, having clogP values below that of minodronate, showed 
almost the same level of activity as minodronate. It is diffi-
cult to interpret the SAR of these compounds using only 
their activity in inhibiting bone resorption. Now, however, 
use of the three-dimensional structure of FPPS, the target of 
N-BPs, has clarified this issue. Moreover, Dunford et al. 
reported a high correlation between the order of inhibition of 
human FPPS in vitro and antiresorptive activities in vivo 
[14], and Rogers also reported the correlation coefficient (r) 
as 0.95 [44]. In section 2 of this review, we noted that the 
bifurcated hydrogen bonding of the protonated heterocyclic 
nitrogen to the hydroxyl group of Thr201 and the backbone 
carbonyl oxygen of Lys200 is important for the tight binding 
for FPPS (Fig. (3a), (3b) and (3c)). From the molecular 
modeling studies showing that compounds 1, 2 and 3 un-
dergo steric repulsion with the binding pocket of FPPS, it is 
clear that compounds 1-3 cannot make such hydrogen bonds, 
while the protonated heterocyclic nitrogen of compound 4 
can undergo bifurcated hydrogen bonding (Fig. 7). As shown 
in this section, our re-consideration of the SAR of heterocyc-
lic N-BPs in Table 3 is useful in facilitating the further opti-
mization of N-BPs, and proves the importance of identifying 
the drug target. 
6. CONCLUSION 
Although BPs are a major class of drugs for the treatment 
of diseases characterized by excessive osteoclast-mediated 
bone resorption, such as post-menopausal and steroid-
induced osteoporosis, the difficulty of isolating a large num-
ber of purified osteoclasts for biochemical studies and the 
diverse effects of BPs on osteoclasts have meant that the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Molecular modeling studies of compounds 1-4. a) Experimental binding mode of minodronate observed in the crystal structure 
(PDB id: 3B7L). b) Examination of the binding of compound 1 using molecular modeling. c) Examination of the binding of compound 2 
using molecular modeling. d) Examination of the binding of compound 3 using molecular modeling. e) Examination of the binding of com-
pound 4 using molecular modeling. Dashed yellow lines indicate the surface of the binding site of the protein. Red circles are the hydroxyl 
group of Thr201 and the backbone carbonyl oxygen of Lys200. Pink lines indicate the hydrogen bonding favourable to the tight binding to 
FPPS. Steric repulsion, which is unfavourable for binding, is also shown as orange lines. Computational Insights into Binding of Bisphosphates  Current Medicinal Chemistry,  2011 Vol. 18, No. 2      231 
molecular mechanisms of action of these drugs have re-
mained unclear for more than 40 years. As described in this 
review, BPs are classified into two groups, non-N-BPs and 
N-BPs. Several biological efforts have revealed that non-N-
BPs are metabolically incorporated into non-hydrolysable 
ATP and induce osteoclast apoptosis, while the major 
mechanism by which N-BPs inhibit bone resorption is via 
the inhibition of FPPS enzyme Fig. (1). Moreover, structural 
biological efforts, including crystallographic studies, have 
clarified the interactions between FPPS and many N-BPs 
(Table 1). Now, many crystal structures of FPPS complexed 
with N-BPs have been deposited in the PDB, making possi-
ble the computational simulation approaches about N-BPs 
described here, including our own research. 
In this review, we first provided a detailed analysis of the 
molecular interactions between FPPS and six N-BPs, namely 
minodronate, zoledronate, risedronate, ibandronate, alendro-
nate and pamidronate, in their crystal structure Fig. (3). 
These analyses confirmed the structure-activity relationships 
we previously obtained in our synthesis research (Table 3). 
The FMO method has indicated that the following inter-
actions may be important for the potency of N-BPs: (1) hy-
drogen bonding with Thr201 and/or Lys200, where a bifur-
cated bond would increase potency over a single bond, (2) 
CH-O hydrogen bonding with the backbone carbonyl oxygen 
atom of Phe99, and (3)  interaction with the sidechain of 
Phe99. Moreover, the difference in the sidechain could affect 
the electrostatic interaction with the surrounding amino acids 
indirectly. In N-BPs, only minodronate satisfied these condi-
tions, which is likely one reason why minodronate shows the 
highest potency against FPPS among all the N-BPs.  
The hydration of the binding site in FPPS has been inves-
tigated using the binding site analysis in FPPS on the basis 
of the inhomogeneous solvation theory which, by clustering 
the results from an explicit solvent MD, is capable of de-
scribing the entropic and enthalpic contributions to the free 
energies of individual hydration sites. This analysis showed 
that the strong activity of minodronate and ibandronate arises 
from the exclusion of unstable solvating water molecules. 
Although many methods of predicting affinity have been 
proposed, few methods take consideration of the entropy 
contribution of solvating water molecules. Hydration site 
analysis can provide deep insights into the binding between 
protein/ligand, although its prediction of relative binding free 
energies is not particularly accurate. Combinational use with 
QM or MM/GBSA may be desirable. 
The use of three-dimensional structural information of a 
target protein in the process of drug development, which is 
Table 3.  Effects of Minodronate Derivatives in Antiresorptive Activity 
 
P
P
O
OH
OH
OH
O
OH
R2
R1
 
 
compound 
structure of 
R1 group 
structure of 
R2 group 
clogP of 
R group
a) 
antiresorptive activity
b) 
(mg/kg, s.c.) 
minodronate 
OH 
N
N
 
1.468 0.003 
1 
OH 
N
N
 
1.468 >  0.1 
2 
OH 
N
N
 
1.687 >  0.3 
3 
OH 
N
N
 
1.997 >  0.3 
4 
OH 
N
N
 
1.099 < 0.01 
aThe methylene and ethylene groups between aromatic rings and bisphosphonate groups were calculated as methyl and ethyl groups, respectively. 
bAntiresorptive activities were evaluated using the parathyroid hormone (PTH)-induced hypercalcemia model (PIH model) [1]. 232    Current Medicinal Chemistry,  2011 Vol. 18, No. 2  Ohno et al. 
also called SBDD, is a highly attractive strategy for pharma-
ceutical companies. The availability of new crystal structures 
of drug targets is therefore of broad general interest in the 
context of the rational development of potent inhibitors, and 
the identification of the drug target, as well as their structural 
determination, are thought to be crucial steps in recent ra-
tional drug research. Because many approaches to target 
profiling of small molecules are used in both academic and 
pharmaceutical research laboratories, it is clear that many 
targets of drugs in clinical use or development will be found. 
In this review, we show a detailed analysis of the energetic 
basis of molecular recognition between FPPS and N-BPs. It 
is expected that similar research on the analysis of interac-
tions between BP drugs and FPPS will increase in the future, 
and facilitate further drug research. 
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FPPS  =  Farnesyl Pyrophosphate Synthase  
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ITC  =  Isothermal titration calorimetry 
N-BPs =  Nitrogen-containing  BPs 
PIEDA  =  Pair interaction energy decomposition analysis 
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